Search

Displaying results 4051 - 4060 of 10000 in total
  1. Drug

    Glycochenodeoxycholic Acid

    go.drugbank.com/drugs/DB02123
    Experimental

    A bile salt formed in the liver from chenodeoxycholate and glycine, usually as the sodium salt. It acts as a detergent to solubilize fats for absorption and is itself absorbed.

    Categories: N-substituted Glycines, Compounds used in a research, industrial, or household setting
  2. Drug

    Chromous sulfate

    go.drugbank.com/drugs/DB14530
    Approved

  3. Drug

    Rotavirus vaccine

    go.drugbank.com/drugs/DB10276
    ApprovedInvestigational

    [Label] Rotavirus vaccines are 90% effective in protecting against severe rotavirus infection.[L1117]

  4. Drug

    Paritaprevir

    go.drugbank.com/drugs/DB09297
    ApprovedInvestigational

    In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) recommend Paritaprevir as a first line … Depending on the genotype, Paritaprevir is often used in combination with other antivirals such as [DB09296], [DB09183], [DB00503], and [DB00811], with the intent to cure, or achieve a sustained virologic

    Synonyms: (2R,6S,12Z,13aR,14aR,16aS)-N-(cyclopropanesulfonyl)-6-[(5-methylpyrazine-2-carbonyl)amino]-5,16-dioxo-2-[(phenanthridin-6-yl)oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo
  5. Drug

    Maltotetraose

    go.drugbank.com/drugs/DB02237
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Mirococept

    go.drugbank.com/drugs/DB06492
    Experimental

    It consists of the first three short consensus domains of human complement receptor 1 (CR1), manufactured in recombinant bacteria and modified with a membrane-targeting amphiphilic peptide based on the … It is a truncated form of the human Complement Receptor 1 (CR1) linked to a unique Prodaptin™ construct that regulates the over-production of complement at the cell surface, which occurs in inflammation

  7. Drug

    Coltuximab ravtansine

    go.drugbank.com/drugs/DB06342
    Investigational

    Coltuximab ravtansine (SAR3419) targets CD19 and is being investigated for the treatment of acute lymphoblastic leukemia (ALL).

  8. Drug

    Abetimus

    go.drugbank.com/drugs/DB06662
    Investigational

    Abetimus was developed by La Jolla Pharmaceuticals as an immunosuppressant but was never marketed in American or Europe despite application for marketing authorization in the mid-2000s.

  9. Drug

    Gallium maltolate

    go.drugbank.com/drugs/DB05420
    Investigational

    Gallium maltolate is Titan’s novel oral agent in development for the potential treatment of chronic bacterial infections, bone disease and cancer.

  10. Drug

    SNS-314

    go.drugbank.com/drugs/DB06134
    Investigational

    SNS-314 inhibits tumor growth in a variety of preclinical models, and it is now being tested in single agent Phase 1 studies in patients with advanced solid tumours.